All eyes are on Evotec SE as it prepares to release its complete 2025 annual report on April 8. This publication carries exceptional weight for the biotechnology firm, serving as the first substantial indicator of whether its ongoing corporate transformation is gaining real traction. This follows a volatile year that saw the company’s share price decline by approximately 35 percent.
Preliminary figures released in March established an initial baseline. Group revenues reached about €788 million, landing at the upper end of the company’s own forecast, with adjusted EBITDA coming in at roughly €41 million. However, these consolidated numbers mask divergent performances across its business units. While the core Drug Discovery & Platform Development segment contracted by 13 percent and recorded an operational loss, the Biologics division posted robust growth of 40 percent.
Restructuring Details and Financial Flexibility
The upcoming report is anticipated to provide the first comprehensive financial details on the “Horizon” restructuring initiative. This strategic program involves consolidating Evotec’s global network down to ten key sites and eliminating up to 800 positions. Management estimates the associated cash expenditures will total around €100 million between 2026 and 2028. They project the first positive operational impacts will materialize in the second half of 2026, with full implementation expected by the end of 2027. The end goal is annualized cost savings of approximately €75 million to bolster long-term profitability.
A recent transaction has strengthened Evotec’s balance sheet, providing additional strategic flexibility. The completed sale of its Biologics site in Toulouse to Sandoz generated about $350 million in immediate cash proceeds. The deal also includes potential future payments from licenses and milestones that could exceed $300 million.
Should investors sell immediately? Or is it worth buying Evotec?
Cautious Outlook Contrasts with Market Expectations
Investor focus remains sharply fixed on the guidance for 2026, which represents a central point of uncertainty. Company projections call for revenues between €700 and €780 million—a decrease from the prior year—and an adjusted EBITDA margin of just €0 to €40 million. This outlook fell short of analyst consensus, which had averaged above €80 million. The significant gap between internal forecasts and market expectations helps explain why the equity is currently trading around 26 percent below its 50-day moving average.
Research analyst opinions reflect this climate of caution. Berenberg and RBC Capital Markets identify potential in the company’s leaner future structure, issuing price targets of €10. Deutsche Bank maintains a more conservative stance with a €6 target.
On the shareholder registry, Goldman Sachs recently increased its stake to 6.12 percent, more than doubling its previously reported position. Significant holdings are also maintained by investment firms Triton and Mubadala, each controlling over 5 percent of the company.
The April 8 report will be judged on how convincingly Evotec outlines the progress of its cost-saving plan and the sustained momentum in its Biologics operation. The next concrete data point for the market will arrive with the Q1 trading update scheduled for early May.
Ad
Evotec Stock: Buy or Sell?! New Evotec Analysis from March 25 delivers the answer:
The latest Evotec figures speak for themselves: Urgent action needed for Evotec investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.
Evotec: Buy or sell? Read more here...
